Cyclized Hexapeptide-9 0.002% Outperforms Same-Dose Retinol 2.1x in Crow's Feet Over 56 Days
SKIN

Cyclized Hexapeptide-9 0.002% Outperforms Same-Dose Retinol 2.1x in Crow's Feet Over 56 Days

By Sophie · · Journal of Cosmetic Dermatology (Wiley) 2026
KO | EN

Cyclized hexapeptide-9 (CHP-9) 0.002% serum applied twice daily for 56 days outperformed an identically dosed retinol serum across every measured outcome in a 96-person randomized, double-blinded, active-and-vehicle-controlled clinical trial published in the Journal of Cosmetic Dermatology (2026). Crow’s feet count dropped by 2.20 lines versus retinol’s 1.04 (2.1x), forehead wrinkles by 2.88 versus 1.05 (2.7x), hydration rose 9.44 units versus 4.22 (2.2x), and TEWL (transepidermal water loss) fell 3.93 g/h/m² versus 1.59 (2.5x). Zero adverse events across all three arms. Crucially, retinol’s effects plateaued early while CHP-9’s effects continued to compound across the trial window.

The study enrolled 96 Asian adults aged 30 to 55, randomized 1:1:1 to CHP-9, retinol, or vehicle, with 91 completing the 56-day protocol. CHP-9 was superior on every endpoint: crow’s feet -2.20 vs -1.04 (2.1x), forehead wrinkles -2.88 vs -1.05 (2.7x), wrinkle area -3.95 mm² vs -2.23 (1.8x), hydration +9.44 vs +4.22 (2.2x), TEWL -3.93 g/h/m² vs -1.59 (2.5x), elasticity (R2) +0.05 vs +0.02 (2.5x). Adverse events: zero in all three arms.

Retinol — The Anti-Aging Reference Standard for a Generation

Why retinol became the gold standard:

  • Vitamin A derivative. Clinical data accumulating since the 1970s
  • Stimulates type I and III collagen synthesis
  • Accelerates keratinocyte turnover
  • Modulates sebaceous activity (acne benefit)
  • Inhibits melanin production (brightening)

Clear limitations:

  • Irritation (erythema, peeling, scaling) in 20-40% of users
  • Contraindicated in pregnancy and lactation
  • Increased UV sensitivity, mandating strict sunscreen use
  • 4-6 week “purge” phase
  • Visible results typically require 0.5%+ doses, with proportional irritation

Why 0.002% matters:

  • Standard OTC retinol: 0.025-1.0%
  • Prescription tretinoin: 0.025-0.1%
  • This study’s 0.002% is an ultra-low dose chosen to minimize irritation. CHP-9 winning at the same dose is the key signal

CHP-9 — Next-Generation Cyclic Peptide

What it is:

  • Six amino acids bonded in a cyclic (ring) configuration
  • Unlike linear peptides, cyclic structure confers superior stability
  • Resistant to enzymatic degradation
  • Better skin penetration

Mechanism (peptide signaling):

  • Direct signaling to dermal fibroblasts
  • Upregulates collagen synthesis gene expression
  • Increases elastin production
  • Boosts HAS2 (hyaluronic acid synthase 2)
  • Elevates SOD2 (antioxidant enzyme)

How it differs from retinol:

  • Retinol: binds nuclear receptors (RAR/RXR), triggers gene expression with irritation and keratinization as side effects
  • CHP-9: surface-receptor-mediated signaling that produces collagen response without inflammatory cascade

Why effects compound over time:

  • Retinol: rapid initial change, plateau by week 4-6
  • CHP-9: collagen neogenesis accumulates, gap widens at day 56
  • Likely larger gaps at 6 and 12 months

Clinical Results — Superiority Across Every Endpoint

1. Crow’s feet -2.20 vs -1.04 lines (2.1x):

  • The first dynamic wrinkles to appear
  • Quantified by digital image analysis (VISIA or equivalent)
  • Absolute count reduction at day 56
  • Top concern area for late-30s to 40s women

2. Forehead wrinkles -2.88 vs -1.05 (2.7x):

  • Horizontal lines from frontalis contraction
  • Deep wrinkles also reduced
  • Meaningful in an area where non-injectable options have been limited

3. Wrinkle area -3.95 mm² vs -2.23 (1.8x):

  • Area, not just count
  • Composite of depth and length
  • 1.8x gap is clinically clear advantage

4. Hydration +9.44 vs +4.22 (2.2x):

  • Corneometer measurement
  • Offsets retinol’s classic dryness drawback
  • CHP-9 strengthens water retention, likely via HAS2

5. TEWL -3.93 vs -1.59 g/h/m² (2.5x):

  • TEWL: lower equals better barrier
  • Retinol typically raises TEWL (weakens barrier)
  • CHP-9 fortifies barrier — a fundamental differentiator

6. Elasticity (R2) +0.05 vs +0.02 (2.5x):

  • Cutometer measurement
  • Marker of collagen and elastin neogenesis
  • Meaningful change at just 56 days

7. Zero adverse events across all arms:

  • No irritation, peeling, erythema, or contact dermatitis
  • Partly attributable to 0.002% ultra-low dosing
  • Pregnancy and lactation safety needs further validation

Why This Matters for Asian Skin

Asian skin characteristics:

  • Thinner stratum corneum compared with Caucasian skin
  • Higher melanin activity, elevating post-inflammatory hyperpigmentation (PIH) risk
  • Larger pores and higher sebum
  • Retinol side effects appear more frequently

Direct applicability to Korean, Japanese, Chinese women:

  • All 96 subjects were Asian
  • Ages 30-55 — the start-to-peak window for anti-aging care
  • Fills a real data gap

Asian market implications:

  • Accelerates the K-beauty peptide trend
  • Expect expanded peptide lines at Olive Young, MatsuKiyo
  • Possibility that consumers skip retinol entry and go straight to CHP-9

Limitations and Practical Application

Study limitations:

  • 56 days is short, no 6 or 12 month data
  • Single ultra-low dose (0.002%), no dose-response curve
  • Same-dose comparison only, not against typical 0.025% or 0.1% retinol
  • Single ethnic group (Asian), limited generalizability
  • Cyclic peptide stabilization is expensive, will raise product prices

Practical use:

  • If retinol irritation is unmanageable: CHP-9 alone
  • Aggressive anti-aging needed: retinol (PM) + CHP-9 (AM)
  • During pregnancy or lactation: CHP-9 alone, pending further safety data
  • New users: start with 0.002% ultra-low dose

The Bigger Picture — The Peptide Era Begins

Why peptides are next-generation candidates:

  • Overcome retinol’s limitations (irritation, pregnancy contraindication)
  • Target-specific signaling (collagen, elastin, HA each independently signaled)
  • Stability and formulation advances (cyclic, encapsulation)
  • Molecular design is feasible, can be tuned to targets

Signaling vs carrier vs neurotransmitter peptides:

  • CHP-9: signaling (collagen)
  • Matrixyl: signaling with mild irritation
  • Copper peptide (GHK-Cu): carrier (copper delivery)
  • Acetyl hexapeptide-8 (Argireline): neurotransmitter blocker (Botox-like)

Outlook for the next 12 months:

  • More cyclic peptides entering clinical trials
  • Multi-peptide combinations proliferating
  • Peptide-retinol synergy studies
  • Molecular weight and penetration optimization

The CHP-9 data sends one clear message: at the same dose, a peptide outperformed retinol across every measurement. The zero-adverse-event profile is the more meaningful finding. Accumulating efficacy without irritation, validated in a head-to-head clinical comparison.